Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915683 | 0.88 | KCNMA1 (0.49) | KCNMA1PKMALDH1A1LMNACES2 | |
| SCHEMBL19848307 | 0.85 | KCNMA1 (0.62) | KCNMA1PKMALDH1A1LMNAGALK1 | |
| SCHEMBL19911622 | 0.83 | KCNMA1 (0.57) | KCNMA1PKMALDH1A1L3MBTL1GAA | |
| SCHEMBL19848238 | 0.82 | KDM4E (0.44) | KCNMA1PKML3MBTL1GAA | |
| SCHEMBL19911475 | 0.82 | KCNMA1 (0.56) | KCNMA1PKMALDH1A1LMNAMAPT | |
| SCHEMBL19848281 | 0.79 | F12 (0.49) | KCNMA1ALDH1A1MAPTNPSR1L3MBTL1 | |
| SCHEMBL19915883 | 0.78 | KCNMA1 (0.41) | KCNMA1PKMALDH1A1GAA | |
| SCHEMBL4963445 | 0.78 | GAA (0.58) | KCNMA1ALDH1A1MAPTNPSR1HTT | |
| SCHEMBL19911551 | 0.77 | MGAM (0.49) | KCNMA1ALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL3279805 | 0.76 | PKM (1.00) | KCNMA1PKMALDH1A1LMNAGALK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | KCNMA1 525/4885PKM 2292/4885ALDH1A1 3497/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | KCNMA1 525/4885PKM 2292/4885ALDH1A1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.